Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1).
Mañós M, Giralt J, Rueda A, Cabrera J, Martinez-Trufero J, Marruecos J, Lopez-Pousa A, Rodrigo JP, Castelo B, Martínez-Galán J, Arias F, Chaves M, Herranz JJ, Arrazubi V, Baste N, Castro A, Mesía R. Mañós M, et al. Oral Oncol. 2017 Jul;70:58-64. doi: 10.1016/j.oraloncology.2017.04.004. Epub 2017 Apr 17. Oral Oncol. 2017. PMID: 28427761 Free article. Review.
Phase II study of panitumumab and paclitaxel as first-line treatment in recurrent or metastatic head and neck cancer. TTCC-2009-03/VECTITAX study.
Del Barco Morillo E, Mesía R, Adansa Klain JC, Vázquez Fernández S, Martínez-Galán J, Pastor Borgoñon M, González-Rivas C, Caballero Daroqui J, Berrocal A, Martínez-Trufero J, Vera R, Cruz-Hernández JJ; Spanish Head And Neck Cancer Cooperative Group (TTCC). Del Barco Morillo E, et al. Oral Oncol. 2016 Nov;62:54-59. doi: 10.1016/j.oraloncology.2016.09.009. Epub 2016 Oct 8. Oral Oncol. 2016. PMID: 27865372 Clinical Trial.
Could the Addition of Cetuximab to Conventional Radiation Therapy Improve Organ Preservation in Those Patients With Locally Advanced Larynx Cancer Who Respond to Induction Chemotherapy? An Organ Preservation Spanish Head and Neck Cancer Cooperative Group Phase 2 Study.
Mesía R, Garcia-Saenz JA, Lozano A, Pastor M, Grau JJ, Martínez-Trufero J, Lambeaz J, Martínez-Galán J, Mel JR, González B, Vázquez S, Mañós M, Taberna M, Cirauqui B, Del Barco E, Casado E, Rubió-Casadevall J, Rodríguez-Jaráiz A, Cruz JJ; Spanish Head And Neck Cancer Cooperative Group (Study TTCC-2007/02). Mesía R, et al. Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):473-480. doi: 10.1016/j.ijrobp.2016.11.016. Epub 2016 Nov 17. Int J Radiat Oncol Biol Phys. 2017. PMID: 28011050 Clinical Trial.
TTCC-2019-02: real-world evidence of first-line cetuximab plus paclitaxel in recurrent or metastatic squamous cell carcinoma of the head and neck.
Rubió-Casadevall J, Cirauqui Cirauqui B, Martinez Trufero J, Plana Serrahima M, García Castaño A, Carral Maseda A, Iglesias Docampo L, Pérez Segura P, Ceballos Lenza I, Gutiérrez Calderón V, Fuster Salvà J, Pena Álvarez C, Hernandez I, Del Barco Morillo E, Chaves Conde M, Martínez Galán J, Durán Sánchez M, Quiroga V, Ortega E, Mesia R. Rubió-Casadevall J, et al. Among authors: martinez galan j. Front Oncol. 2023 Aug 1;13:1226939. doi: 10.3389/fonc.2023.1226939. eCollection 2023. Front Oncol. 2023. PMID: 37601652 Free PMC article.
Phase 4 Multinational Multicenter Retrospective and Prospective Real-World Study of Nivolumab in Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck.
Gogate A, Bennett B, Poonja Z, Stewart G, Medina Colmenero A, Szturz P, Carrington C, Castro C, Gemmen E, Lau A, Carral Maseda A, Winquist E, Arrazubi V, Hao D, Cook A, Martinez Galan J, Ugidos L, Fernández Garay D, Gutierrez Abad D, Metcalf R. Gogate A, et al. Among authors: martinez galan j. Cancers (Basel). 2023 Jul 9;15(14):3552. doi: 10.3390/cancers15143552. Cancers (Basel). 2023. PMID: 37509217 Free PMC article.
Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.
Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E; Spanish Cooperative Group of Treatment of Digestive Tumors (TTD). Irigoyen A, et al. Eur J Cancer. 2017 Apr;75:73-82. doi: 10.1016/j.ejca.2016.12.032. Epub 2017 Mar 7. Eur J Cancer. 2017. PMID: 28222309 Clinical Trial.
Pancreatic ductal adenocarcinoma: metastatic disease.
Muñoz Martín AJ, Adeva J, Martínez-Galán J, Reina JJ, Hidalgo M. Muñoz Martín AJ, et al. Clin Transl Oncol. 2017 Dec;19(12):1423-1429. doi: 10.1007/s12094-017-1690-6. Epub 2017 Jun 16. Clin Transl Oncol. 2017. PMID: 28623515 Review.
Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2.
Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M. Macarulla T, et al. J Clin Oncol. 2019 Jan 20;37(3):230-238. doi: 10.1200/JCO.18.00089. Epub 2018 Dec 4. J Clin Oncol. 2019. PMID: 30523758 Clinical Trial.
50 results